Page 57 - Haematologica - Vol. 105 n. 6 - June 2020

EBMT ALWP recommendation for allo-SCT for FLT3 AML
as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocyt- ic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106(10):3658-3665.
68. Meshinchi S, Arceci RJ, Sanders JE, et al. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood. 2006;108(1):400; author reply 400-401.
69. DeZern AE, Sung A, Kim S, et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant. 2011;17(9):1404-1409.
70. Sengsayadeth SM, Jagasia M, Engelhardt BG, et al. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant. 2012;47(12):1535-1537.
71. Kayser S DK, Krauter J, Kohne C, et al. Allogeneic transplantation from matched related and unrelated donors in first com- plete remission in younger adult AML patients with FLT3 internal tandem duplica- tions. Bone Marrow Transplant. 2011;18(6):395-400.
72. Hemmati P TT, Vuong LG, le Coutre PD, Dorken B, Arnold R. Allogeneic stem cell transplantation for cytogenetically normal acute myeloid leukemia: impact of FLT3 and NPM1 mutational status. Blood. 2013; 122(21):2104.
73. Liegel J, Courville E, Sachs Z, Ustun C. Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cyto- toxic effect. Haematologica. 2014;99(11): e222-224.
74. Deol A, Sengsayadeth S, Ahn KW, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016;122(19):3005-3014.
75. DeZern AE, Sung A, Kim S, et al. Patients with FLT3/ITD AML may benefit from allo- geneic transplant in first remission: out- comes from a consecutive series of patients at a single institution. Blood. 2010;116 (21):2172.
76. Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374 (5):422-433.
77. Terwijn M, van Putten WLJ, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31(31):3889-3897.
78. Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275-1291.
79. Chang Y-J, Huang X-J. Haploidentical stem cell transplantation: anti-thymocyte globu- lin-based experience. Semin Hematol. 2016;53(2):82-89
80. McCurdy SR, Kasamon YL, Kanakry CG, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017; 102(2):391-400.
81. Zhang Y-Y, Mo X-D, Zhang X-H, et al. FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in
AML patients. Bone Marrow Transplant.
2019;54(9):1462-1470.
82. Schiller GJ, Tuttle P, Desai P. Allogeneic
hematopoietic stem cell transplantation in FLT3-ITD-positive acute myelogenous leukemia: the role for FLT3 tyrosine kinase inhibitors post-transplantation. Biol Blood Marrow Transplant. 2016;22(6):982-990.
83. Shouval R, Fein JA, Labopin M, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA- matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analy- sis. Lancet Haematol. 2019;6(11):e573-e584.
84. Xuan L, Wang Y, Huang F, et al. Effect of sorafenib on the outcomes of patients with FLT3 ITD acute myeloid leukemia undergo- ing allogeneic hematopoietic stem cell trans- plantation. Cancer. 2018;124(9):1954-1963.
85. Bazarbachi AH, Al Hamed R, Malard F, Mohty M, Bazarbachi A. Allogeneic trans- plant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant. Ther Adv Hematol. 2019;10: 2040620719882666.
86. Williams PL, Webb C. The Delphi tech- nique: a methodological discussion. J Adv Nurs. 1994;19(1):180-186.
87. Couriel DR. Ancillary and supportive care in chronic graft-versus-host disease. Best Pract Res Clin Haematol. 2008;21(2):291-307.
88. Ho AD, Schetelig J, Bochtler T, et al. Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD. Biol Blood Marrow Transplant. 2016;22(3):462-469.
89. Versluis J, In 't Hout FE, Devillier R, et al. Comparative value of post-remission treat- ment in cytogenetically normal AML sub- classified by NPM1 and FLT3-ITD allelic ratio. Leukemia. 2017;31(1):26-33.
90. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 2000;14(4):675- 683.
91. Döhner K, Thiede C, Jahn N, et al. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020;135(5):371-380.
92. Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30(7):735-741.
93. MaY,WuY,ShenZ,ZhangX,ZengD, Kong P. Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review. Clin Transplant. 2015;29(2):149-160.
94. Doubek M, Muzik J, Szotkowski T, et al. Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT). Neoplasma. 2007;54(1):89-94.
95. Lin PH, Lin CC, Yang HI, et al. Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3. Leuk Res. 2013;37(3):287-292.
96. Canaani J, Labopin M, Huang XJ, et al. T-cell replete haploidentical stem cell transplanta- tion attenuates the prognostic impact of
FLT3-ITD in acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018;93(6):736-744.
97. Schmid C, Labopin M, Socie G, et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood. 2015;126(17):2062-2069.
98. Thanarajasingam G, Kim HT, Cutler C, et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(12):1713-1718.
99. Sakaguchi M, Yamaguchi H, Najima Y, et al. Prognostic impact of low allelic ratio FLT3- ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv. 2018;2(20):2744-2754.
100.Oran B, Cortes J, Beitinjaneh A, et al. Allogeneic transplantation in first remission improves outcomes irrespective of FLT3- ITD allelic ratio in FLT3-ITD-positive acute myelogenous leukemia. Biol Blood Marrow Transplant. 2016;22(7):1218-1226.
101.Zhao X, Wang Z, Ruan G, et al. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytom- etry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell trans- plantation. Ann Hematol. 2018;97(6):967- 975.
102.Popescu B, Sheela S, Thompson J, et al. Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemia. Clin Hematol Int. 2019;2(1):27-31.
103.Poire X, Labopin M, Maertens J, et al. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remis- sion: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). J Hematol Oncol. 2017;10(1):20.
104.Laboure G, Dulucq S, Labopin M, et al. Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for inter- mediate-risk AML with FLT3-ITD or wild- type NPM1 and CEBPA without FLT3-ITD. Biol Blood Marrow Transplant. 2012;18(12): 1845-1850.
105.
106.
Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776-2784.
Gaballa S, Saliba R, Oran B, et al. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergo- ing stem cell transplantation. Am J Hematol. 2017;92(4):331-337.
107.Kayser S, Benner A, Thiede C, et al. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Blood Cancer J. 2016;6(7):e449-e449.
108.Pfeiffer T, Schleuning M, Mayer J, et al. Influence of molecular subgroups on out- come of acute myeloid leukemia with nor- mal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. Haematologica. 2013;98(4):518- 525.
109. Gorin NC, Labopin M, Blaise D, et al. Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous
haematologica | 2020; 105(6)
1515